New Releases from NCBI BookshelfAbemaciclib (Verzenio): Therapeutic area: HR-positive, HER2-negative advanced or metastatic breast cancer: Reimbursement Review [Internet].Abemaciclib (Verzenio): Therapeutic area: HR-positive, HER2-negative advanced or metastatic breast cancer: Reimbursement Review [Internet].By admin / January 13, 2026 Post Content